Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increased level of Lp(a) lipoprotein has been identified as a risk factor for coronary artery disease that is highly heritable. The genetic determinants of the Lp(a) lipoprotein level and their relevance for the risk of coronary disease are incompletely understood. METHODS: We used a novel gene chip containing 48,742 single-nucleotide polymorphisms (SNPs) in 2100 candidate genes to test for associations in 3145 case subjects with coronary disease and 3352 control subjects. Replication was tested in three independent populations involving 4846 additional case subjects with coronary disease and 4594 control subjects. RESULTS: Three chromosomal regions (6q26-27, 9p21, and 1p13) were strongly associated with the risk of coronary disease. The LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the strongest association. We identified a common variant (rs10455872) at the LPA locus with an odds ratio for coronary disease of 1.70 (95% confidence interval [CI], 1.49 to 1.95) and another independent variant (rs3798220) with an odds ratio of 1.92 (95% CI, 1.48 to 2.49). Both variants were strongly associated with an increased level of Lp(a) lipoprotein, a reduced copy number in LPA (which determines the number of kringle IV-type 2 repeats), and a small Lp(a) lipoprotein size. Replication studies confirmed the effects of both variants on the Lp(a) lipoprotein level and the risk of coronary disease. A meta-analysis showed that with a genotype score involving both LPA SNPs, the odds ratios for coronary disease were 1.51 (95% CI, 1.38 to 1.66) for one variant and 2.57 (95% CI, 1.80 to 3.67) for two or more variants. After adjustment for the Lp(a) lipoprotein level, the association between the LPA genotype score and the risk of coronary disease was abolished. CONCLUSIONS: We identified two LPA variants that were strongly associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease. Our findings provide support for a causal role of Lp(a) lipoprotein in coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [227]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We found the association between LDLR genotype and Lp(a) levels remained significant after accounting for the rs10455872 genotype that tags a narrower range of LPA alleles10, but we could not directly assess LPA KIV2 copy number variants in the UKBB cohort to assess for a difference between groups.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple genome-wide association studies (GWAS) did not find an association between Lp(a) levels and common variants at the LDLR locus10,46,47, but a recent GWAS of 371,212 individuals in the UK Biobank did48.”
From Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C [72,73].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Genomic Control for Association Studies
Devlin, B., & Roeder, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00997.x · Cited by 3,162
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Genomewide Association Analysis of Coronary Artery Disease
Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., Dixon, R. J., Meitinger, T., Braund, P., Wichmann, H.-E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072366 · Cited by 2,044
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., Jonasdottir, A., Sigurdsson, A., Baker, A., Palsson, A., et al. (2007) · Science · doi:10.1126/science.1142842 · Cited by 1,594
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Self-citationCommon variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citation
Research works printed but not linked: 1
- Siekmeier R, 1996, Lab Medizin, 20, 294
Cited by
Items 701–800 of 1,004
Morgan, B. M., Brown, A., Deo, N., Harrop, T. W. R., Taiaroa, G., Mace, P. D., Wilbanks, S. M., Merriman, T. R., Williams, M. J. A., & McCormick, S. P. A. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m094540 · Cited by 25
Stefanutti, C., Pisciotta, L., Favari, E., Giacomo, S. D., Vacondio, F., Zenti, M. G., Morozzi, C., Berretti, D., Mesce, D., Vitale, M., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.05.002 · Cited by 22
Zoungas, S., Curtis, A. J., McNeil, J. J., & Tonkin, A. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.86 · Cited by 26
Riches‐Suman, K., Franklin, L., Maqbool, A., Peckham, M., Adams, M., Bond, J., Warburton, P., Feric, N. T., Koschinsky, M. L., O'Regan, D. J., et al. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.021 · Cited by 22
Kathiresan, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.967 · Cited by 22
“In addition, polymorphisms that increase plasma lipoprotein(a) consistently confer increased risk for ASCVD (21–23).”
BackgroundLp(a) Lipoprotein Redux — From Curious Molecule to Causal Risk Factor
Kathiresan, S. (2009) · New England Journal of Medicine · doi:10.1056/nejme0910792 · Cited by 22
Behera, S., Belyeu, J. R., Chen, X., Paulin, L. F., Nguyen, N. Q. H., Newman, E., Mahmoud, M., Menon, V. K., Qi, Q., Joshi, P., et al. (2023) · doi:10.1101/2023.04.24.538128 · Cited by 21
Kaur, G., Berman, A. N., Biery, D. W., Besser, S. A., Wu, W. Y., Weber, B., Honigberg, M. C., Nasir, K., Gulati, M., Carli, M. F. D., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.035353 · Cited by 21
Vuorio, A. F., Watts, G. F., & Kovanen, P. T. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx546 · Cited by 24
Lipoprotein(a) is not associated with venous thromboembolism risk
Kunutsor, S. K., Mäkikallio, T. H., Kauhanen, J., Voutilainen, A., & Laukkanen, J. A. (2019) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2019.1612087 · Cited by 21
“Consistently, several well-designed large-scale epidemiological studies have shown Lp(a) to be independently associated with cardiovascular outcomes [3-6] with some suggestions of causal relationships reported [4-6].”
BackgroundPluimakers, V. G., van Santen, S. S., Fiocco, M. F., Bakker, M.-C., van der Lely, A. J., van den Heuvel‐Eibrink, M. M., & Neggers, S. J. C. M. M. (2021) · Obesity Reviews · doi:10.1111/obr.13312 · Cited by 21
New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Nestel, P. J., Loh, W. J., Ward, N. C., & Watts, G. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac541 · Cited by 21
Lipoprotein(a), family history of cardiovascular disease, and incidence of heart failure
Wang, H., Zhang, N., Liu, Y., Xia, T.-L., Chen, G., Yang, J., & Li, F. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100398 · Cited by 21
Manikpurage, H. D., Paulin, A., Girard, A. S., Eslami, A., Mathieu, P., Thériault, S., & Arsenault, B. J. (2023) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.123.004137 · Cited by 21
Lipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician
Jha, M., Raber, I., & Gelfand, E. V. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.034 · Cited by 22
Lippi, G., Franchini, M., & Targher, G. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.01.018 · Cited by 21
“However, the association between the apo(a) genotype score and CHD risk became not significant after adjustment for Lp(a) level [21].”
BackgroundMethodGenetics of Complex Airway Disease
Cookson, W., & Moffatt, M. F. (2011) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201101-003ms · Cited by 25
“For example, a Mendelian randomization strategy has been used recently to show that SNPs modulating C-reactive protein do not cause coronary heart disease (13), whereas a causal role for Lp(a) has been substantiated (14).”
MethodMirhafez, S. R., Avan, A., Pasdar, A., Khatamianfar, S., Hosseinzadeh, L., Ganjali, S., Movahedi, A., Pirhoushiaran, M., Gómez‐Mellado, V. E., Rosace, D., et al. (2016) · PubMed Central · Cited by 32
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Preiss, D., & Mafham, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4178-y · Cited by 23
“In addition, it is well recognised that PCSK9 inhibition leads to a reduction in levels of lipoprotein(a), an atherogenic lipid particle causally implicated in CVD [23], of about 20–30% [24, 25].”
BackgroundInfluentialVery low lipoprotein(a) and increased mortality risk after myocardial infarction
Wohlfahrt, P., Jenča, D., Melenovský, V., Franeková, J., Jabor, A., Šramko, M., Staněk, V., Želízko, M., Poledne, R., Pitha, J. V., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.012 · Cited by 21
Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type‐2 Diabetes
Nakhjavani, M., Morteza, A., Esteghamati, A., Khalilzadeh, O., Zandieh, A., & Safari, R. (2010) · Lipids · doi:10.1007/s11745-010-3513-1 · Cited by 22
“It is mainly determined genetically, depending on apoprotein (a) genotype [ 9 , 10].”
BackgroundMissing heritability may be hiding in repeats
Gymrek, M., & Goren, A. (2021) · Science · doi:10.1126/science.abl7794 · Cited by 21
Chen, T., Wang, Z., Xie, J., Xiao, S., Li, W., & Liu, N. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.033 · Cited by 20
Behera, S., Belyeu, J. R., Chen, X., Paulin, L. F., Nguyen, N. Q., Newman, E., Mahmoud, M., Menon, V. K., Qi, Q., Joshi, P. H., et al. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-02024-0 · Cited by 21
“KIV-2 CN allele length has been shown to be inversely associated with increased CVD risk in some populations [13–15].”
BackgroundFAN, W., Wu, C., & Wong, N. D. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004631 · Cited by 20
Variantes genéticas, riesgo cardiovascular y estudios de asociación de genoma completo
Companioni, O., Rodríguez‐Esparragón, F., Fernández‐Aceytuno, A. M., & Pérez, J. C. R. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.01.010 · Cited by 22
Durrington, P. N., Schofield, J. D., Siahmansur, T. J., & Soran, H. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000096 · Cited by 20
“A powerful demonstration of the molecular bases of such observations has been reported more recently [10,17].”
BackgroundСеменова, А. Е., Сергиенко, И. В., García-Giustiniani, D. A., Monserrat, L., Попова, А. Б., Нозадзе, Д. Н., & Владиславович, Е. М. (2020) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd7020016 · Cited by 20
“All seven carriers who were heterozygous for the Ile1891Met polymorphism (rs3798220) in the lipoprotein(a) (LPA) gene [16] had elevated lipoprotein(a) [Lp(a)] levels, of 117.”
BackgroundClarke, R., Hammami, I., Sherliker, P., Valdés‐Márquez, E., Watkins, H. C., Hill, M., Yang, X., Tsimikas, S., & Hopewell, J. C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1020 · Cited by 20
Self-citationKritharides, L., Nordestgaard, B. G., Tybjærg‐Hansen, A., Kamstrup, P. R., & Afzal, S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01049 · Cited by 21
Lipoprotein(a): There’s Life in the Old Dog Yet
Kronenberg, F. (2014) · Circulation · doi:10.1161/circulationaha.113.007256 · Cited by 20
“Studies using SNPs that tag a subfraction of the small apo(a) isoforms took the same line.(6) This concept using genetic variants that determine an important fraction of the risk factor under suspicion to demonstrate an association with the outcome of interest was later called Mendelian Randomization.”
Melita, H., Manolis, A. A., Manolis, T. A., & Manolis, A. S. (2022) · PubMed · doi:10.1097/fjc.0000000000001160 · Cited by 19
Park, J. S., Cho, K. H., Hong, Y. J., Kim, M. C., Sim, D. S., Kim, J. H., Ahn, Y., & Jeong, M. H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e102 · Cited by 20
Koskinas, K. C., Häner, J. D., Ueki, Y., Otsuka, T., Lønborg, J., Shibutani, H., Kakizaki, R., Kaiser, C. A., van Geuns, R., Ondracek, A. S., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.016683 · Cited by 19
Lipoprotein(a) and Arterial Stiffness Parameters
Sorokin, A. V., & Kotani, K. (2015) · Pulse · doi:10.1159/000438733 · Cited by 19
Hyperlipoproteinemia(a): Clinical significance and treatment options
Berthold, H. K., & Gouni‐Berthold, I. (2013) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.10.037 · Cited by 21
Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity
Onat, A., Dönmez, İ., Karadeniz, Y., Çakır, H., & Kaya, A. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.910114 · Cited by 19
“Using somewhat modified criteria, increased CAD risk was confirmed in the large prospective EPIC-Norfolk study in which nonfasting triglycerides were used [28].”
BackgroundInfluentialAnalysis with the exome array identifies multiple new independent variants in lipid loci
Kanoni, S., Masca, N. G. D., Stirrups, K. E., Varga, T. V., Warren, H. R., Scott, R. A., Southam, L., Zhang, W., Yaghootkar, H., Müller‐Nurasyid, M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw227 · Cited by 21
“In the LPA locus, the missense variant rs3798220 (p.I1891M) previously associated with Lp(a) lipoprotein levels and CAD (14) had the strongest signal for LDL-C.”
BackgroundSelf-citationSun, D., Zhou, B., Zhao, X., Li, S., Zhu, C., Guo, Y., Gao, Y., Wu, N., Liu, G., Dong, Q., et al. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22442 · Cited by 19
Lp(a): Addressing a Target for Cardiovascular Disease Prevention
Vasquez, N., & Joshi, P. H. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1182-0 · Cited by 20
Berman, A. N., Biery, D. W., Singh, A., Wu, W. Y., Divakaran, S., DeFilippis, E. M., Hainer, J. M., Blaha, M. J., Cannon, C. P., Polk, D. M., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320931296 · Cited by 19
Berman, A. N., Biery, D. W., Ginder, C. R., Hulme, O. L., Marcusa, D. P., Leiva, O., Wu, W. Y., Singh, A., Divakaran, S., Hainer, J. M., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23456 · Cited by 19
“elevated lipoprotein(a) (Lp(a)) is an independent risk factor for coronary heart disease, ischemic stroke, and calcific aortic valve stenosis.(1-12) With a unique molecular structure hypothesized to be both pro-atherogenic and pro-thrombotic,(13) Lp(a) is composed of a lowdensity lipoprotein-like moiety covalently bou…”
BackgroundKhera, A. V., & Rader, D. J. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.12.003 · Cited by 19
Hovland, A., Aagnes, I., Brekke, O., Flage, J. H., & Lappegård, K. T. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.02.011 · Cited by 19
Santos, P. C., Bueno, C. T., Lemos, P. A., Krieger, J. E., & Pereira, A. C. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-74 · Cited by 19
“Other studies that analyzed the rs10455872 and rs3798220 polymorphisms together reported an increased risk of coronary disease and Lp(a) level that can be explained by these LPA polymorphisms [11,32].”
BackgroundResultSolomon, T., Smith, E. N., Matsui, H., Braekkan, S. K., INVENT Consortium, Wilsgaard, T., Njølstad, I., Mathiesen, E. B., Hansen, J.-B., & Frazer, K. A. (2016) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.115.001327 · Cited by 19
“Some associations were consistent across all the 3 methods, such as LP(a), which carried a large number of variants (Table IX in the Data Supplement) and for which rare variation has previously been associated with the protein level in the blood.(41) Others were only significant in 1 test, such as MMP8 when variants w…”
ResultXu, S., Cheng, J., Li, N., Chen, Y.-N., Cai, M., Tang, S.-S., Huang, H., Zhang, B., Cen, J.-M., Yang, X.-L., et al. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0065-7 · Cited by 19
“Recent studies illustrated that the G allele of rs10455872, and the C allele of rs3798220 in LPA gene significantly elevated the LPA levels in peripheral blood, and the two SNPs in LPA were demonstrated to be the critical risk factors for CAD development, indicating that LPA polymorphisms were associated with CAD risk…”
BackgroundEffects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis
Trenkwalder, T., Nelson, C. P., Musameh, M. D., Mordi, I. R., Kessler, T., Pellegrini, C., Debiec, R., Rheude, T., Lazovic, V., Zeng, L., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.094 · Cited by 18
“Indeed, the LPA locus and rs10455872 specifically have also been found to be strongly associated with CAD [22].”
BackgroundMcPherson, R. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.08.017 · Cited by 24
The Prevalence of Elevated Lipoprotein(a) in Patients Presenting With Coronary Artery Disease
Oo, H. H., Giovannucci, J., O’Brien, R. C., & Hare, D. L. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.03.005 · Cited by 18
Junco-Vicente, A., Solache-Berrocal, G., Río-García, Á. D., Rollé, V., Rodríguez, S. A., Morís, C., Martín, M., & Rodríguez, I. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.989539 · Cited by 18
“In fact, a causal association between elevated levels of lipoprotein(a) and increased risk of myocardial infarction or coronary artery disease has been demonstrated (42, 43).”
BackgroundSchumann, F., Kassner, U., Spira, D., Zimmermann, F. F., Bobbert, T., Steinhagen‐Thiessen, E., & Hollstein, T. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.04.134 · Cited by 18
Aguchem, R. N., Okagu, I. U., Okorigwe, E. M., Uzoechina, J. O., Nnemolisa, S. C., & Ezeorba, T. P. C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122823 · Cited by 18
Athanasiadis, G. I., Sabater‐Lleal, M., Buil, A., Souto, J. C., Borrell, M., Lathrop, M. G., Watkins, H. C., Almasy, L. A., Hamsten, A., & Soria, J. M. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12120 · Cited by 19
Self-citationGirelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 19
“The scenario has recently clarified by the identification of LPA genetic variants associated with both elevated circulating Lp(a) and increased CAD risk [83], particularly in prospective studies [84].”
BackgroundYan, J., Pan, Y., Xiao, J., Ma, W., Li, L., Zhong, M., Long, H., Kong, F., & Shao, W. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190120 · Cited by 18
Lipoprotein(a) Gene Polymorphism Increases a Risk Factor for Aortic Valve Calcification
Özkan, U., Özçelik, F., Yildiz, M., & Budak, M. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6030031 · Cited by 19
“The rs3798220(C) polymorphism is a predictor for coronary heart disease in both genders, and it reduces the effect of low dose aspirin therapy in female carriers of the C allele with higher levels of plasma Lp(a) [37,40].”
BackgroundJia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 19
Hu, X., Cristino, J. R., Gautam, R., Mehta, R. K., Amari, D. T., Heo, J. H., Wang, S., & Wong, N. D. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100476 · Cited by 18
Genetics of Lipid Traits and Relationship to Coronary Artery Disease
Keenan, T. E., & Rader, D. J. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0396-9 · Cited by 19
“The common LPA variants rs10455872 and rs3798220 have been shown to be strongly and independently associated with higher Lp(a) levels, reduced KIV-2 copy number, smaller Lp(a) size, and increased CAD risk [80].”
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
“The plasma concentration of Lp(a) is highly heritable and genetically determined [43].”
BackgroundDoes lifestyle contribute to disease severity in patients with inherited lipid disorders?
Arsenault, B. J., Perrot, N., & Couture, P. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000387 · Cited by 20
Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance
Vassiliou, V. S., Flynn, P. D., Raphael, C. E., Newsome, S., Khan, T. Z., Ali, A., Halliday, B. P., Bruengger, A. A. S., Malley, T. S., Sharma, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181077 · Cited by 18
“Recently, genome wide association studies have identified more frequent genetic variations such as the SNP rs104555872 at the LPA gene in patients with aortic valve calcification and stenosis and importantly, presence of such genetic variations in the LPA gene led to increased levels of both Lp(a) [27] and clinical ao…”
BackgroundRomagnuolo, R., DeMarco, K., Scipione, C. A., Boffa, M. B., & Koschinsky, M. L. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.002 · Cited by 18
Ma, K. L., Gong, T. K., Hu, Z. B., Zhang, Y., Wang, G. H., Liu, L., Chen, P. P., Lü, J., Lu, C., & Liu, B. C. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0986-2 · Cited by 18
Mohammadi‐Shemirani, P., Sjaarda, J., Gerstein, H. C., Treleaven, D. J., Walsh, M. W., Mann, J. F. E., McQueen, M., Hess, S., & Paré, G. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.291104 · Cited by 18
How Does Elevated Lipoprotein(a) Cause Aortic Valve Stenosis? ∗
Nordestgaard, B. G., & Langsted, A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.045 · Cited by 18
Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia
Langsted, A., & Nordestgaard, B. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01002-0 · Cited by 19
Razavi, A. C., Bhatia, H. S., Blumenthal, R. S., Shapiro, M. D., & Mehta, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16469 · Cited by 18
“These findings support the hypothesis that Lp(a) is not merely a biomarker of cardiovascular risk but a causal factor in ASCVD 29 and CAVD 30 pathogenesis.”
Enkhmaa, B., Anuurad, E., Zhang, W., Li, C., Kaplan, R. C., Lazar, J., Merenstein, D., Karim, R., Aouizerat, B. E., Cohen, M. H., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309137 · Cited by 17
Kashyap, S., Kumar, S., Agarwal, V., Misra, D. P., Rai, M. K., & Kapoor, A. (2018) · Gene · doi:10.1016/j.gene.2018.01.021 · Cited by 17
Cao, Y., Jin, J., Guo, Y., Sun, D., Liu, H., Wu, N., Xu, R., Zhu, C., Liu, G., Dong, Q., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.010 · Cited by 17
Liu, Y.-T., Tantoh, D. M., Wang, L., Nfor, O. N., Hsu, S., Ho, C., Lung, C.-C., Chang, H., & Liaw, Y. (2020) · Nutrients · doi:10.3390/nu12051301 · Cited by 17
“For instance, SNPs account for just a minute fraction (approximately 10–15%) of CHD heritability [1,2,5,12,13].”
BackgroundLipoprotein(a) in clinical practice: A guide for the clinician
Krittanawong, C., Maitra, N. S., Sherbini, A. E., Shah, N. R., Lavie, C. J., Shapiro, M. D., & Virani, S. S. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.07.006 · Cited by 17
Contemporary human genetic strategies in aging research
Bloss, C. S., Pawlikowska, L., & Schork, N. J. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.07.005 · Cited by 20
Rare variants and cardiovascular disease
Wain, L. V. (2014) · Briefings in Functional Genomics · doi:10.1093/bfgp/elu010 · Cited by 18
“This SNP is correlated with short isoforms of apo(a) [32], and low copy number of these repeats is associated with the risk of CAD [32] and MI [33] through an effect on lipoprotein(a) levels [34].”
BackgroundZabalza, M., Subirana, I., Lluís-Ganella, C., Sayols-Baixeras, S., de Groot, E., Arnold, R. J., Cenarro, A., Ramos, R., Marrugat, J., & Elosúa, R. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.10.023 · Cited by 20
Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo
Månsson, M., KALIES, I., Bergström, G. M. L., Schmidt, C., Legnehed, A., Hultén, L. M., Amrot-Fors, L., Gustafsson, D., & Knecht, W. (2014) · Scientific Reports · doi:10.1038/srep05318 · Cited by 19
Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
Hopewell, J. C., Reith, C. A., & Armitage, J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000125 · Cited by 18
“Variation in the LPA gene strongly determines levels of the LDL-like particle lipoprotein(a) [Lp(a)], which is causally associated with coronary artery disease [29].”
BackgroundSelf-citationSafarova, M. S., Fan, X., Austin, E. E., van Zuydam, N., Hopewell, J., Schaid, D. J., & Kullo, I. J. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.312128 · Cited by 17
Self-citationMetabolic dysregulation of trained immunity in immune aging and the impact of dietary patterns
Grigorescu, A., Riza, A., Streață, I., & Netea, M. G. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00153.2025 · Cited by 17
Jafarnezhad, F., Nazarzadeh, A., Bazavar, H., Keramat, S., Ryszkiel, I., & Stanek, A. (2025) · Nutrients · doi:10.3390/nu17162656 · Cited by 16
“Adherence to plant-based eating patterns has been linked to decreased circulating concentrations of lipoprotein (a), an independent cardiovascular risk factor often elevated in patients with MetS [156].”
Ponasenko, A. V., Sinitsky, M. Y., Minina, V. I., Vesnina, A. D., Khutornaya, M. V., Prosekov, A. Y., & Барбараш, О. Л. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020238 · Cited by 18
Wang, Z., Xiao, S., & Liu, N. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117220 · Cited by 16
Wang, P., Yuan, D., Zhang, C., Jia, S., Song, Y., Tang, X., Zhao, X., Gao, R., Xu, B., & Yuan, J. (2023) · iScience · doi:10.1016/j.isci.2023.106117 · Cited by 16
Levstek, T., Karun, T., Likozar, A. R., Šebeštjen, M., & Podkrajšek, K. T. (2023) · Genes · doi:10.3390/genes14030632 · Cited by 16
“before and also after its reduction, especially with statins [3].”
BackgroundImpact of Lipoprotein (a) on Long-Term Outcomes in Patients With Acute Myocardial Infarction
Dai, K., Shiode, N., Yoshii, K., Kimura, Y., Matsuo, K., Jyuri, Y., Tomomori, S., Higaki, T., Oi, K., Kawase, T., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0221 · Cited by 16
Mukherjee, D., & Nissen, S. E. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611267835231210054909 · Cited by 16
Rare damaging CCR2 variants are associated with lower lifetime cardiovascular risk
Georgakis, M. K., Malik, R., Bounkari, O. E., Hasbani, N. R., Li, J., Huffman, J. E., Shakt, G. E., Tack, R. W. P., Kimball, T. N., Asare, Y., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01456-2 · Cited by 17
Prevalence and Correlates of Lipoprotein(a) Testing in a Diverse Cohort of U.S. Adults
Razavi, A. C., Richardson, L. C., Coronado, F., Vesper, H. W., Lyle, A. N., Bhatia, H. S., Tsimikas, S., Quyyumi, A. A., Vaccarino, V., Eapen, D. J., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101826 · Cited by 16
Sharma, A., Kasim, M., Joshi, P. H., Qian, Z., Krivitsky, E. L., Akram, K., Rinehart, S. J., Vazquez, G., Miller, J. C., Rohman, M. S., et al. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-011-9273-3 · Cited by 16
“The role of genetic variability in predisposing to coronary disease was examined in a large genetic study examining 2,100 candidate genes for possible association with coronary disease [20], which found three chromosomal regions Table 4 Comparison of clinical parameters and biomarkers in Caucasians dichotomized by CAC…”
BackgroundLipoprotein(A) Level and Mif Gene Variant Predict Incident Metabolic Syndrome and Mortality
Onat, A., Can, G., Çoban, N., Dönmez, İ., Çakır, H., Ademoğlu, E., Erginel‐Ünaltuna, N., & Yüksel, H. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2015-000003 · Cited by 16
Hanks, L. J., Pelham, J. H., Vaid, S., Casazza, K., & Ashraf, A. P. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.004 · Cited by 16
“Several meta-analyses have provided support for an association between Lp(a) and CVD [41–44].”
BackgroundCurrent and future role of lipoprotein(a) in preventive cardiology
Berman, A. N., & Blankstein, R. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000661 · Cited by 16
“48) for individuals who carry two or more variant Lp(a) alleles [6,13].”
BackgroundPage, M. M., Ellis, K. L., Pang, J., Chan, D. C., Hooper, A. J., Bell, D. A., Burnett, J. R., & Watts, G. F. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.07.029 · Cited by 16
Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative
Chou, E. L., Pettinger, M. B., Haring, B., Mell, M. W., Hlatky, M. A., Wactawski‐Wende, J., Allison, M., Wild, R. A., Shadyab, A. H., Wallace, R. B., et al. (2020) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2020.07.106 · Cited by 16
Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy
Langsted, A., & Nordestgaard, B. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00937-0 · Cited by 16
Németh, Á., Daróczy, B., Juhász, L., Fülöp, P., Harangi, M., & Paragh, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.849197 · Cited by 16
“Previous studies have suggested that high levels of Lp(a) are more common in individuals with FH, further increasing the cardiovascular risk in these patients (Clarke et al., 2009; Kamstrup et al., 2009).”
BackgroundLipoprotein(a) is associated with a larger systemic burden of arterial calcification
Singh, S. S., van der Toorn, J. E., Sijbrands, E. J. G., de Rijke, Y. B., Kavousi, M., & Bos, D. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead057 · Cited by 16
Lipoprotein (a) and myocardial infarction: impact on long-term mortality
Zhang, J., Jia, L., Yang, Y., Xiao, A. Y., & Lin, X. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01841-z · Cited by 17
“In the last decade, data from epidemiological studies and meta-analyses [8], Mendelian randomization studies [9] and genome-wide association studies [10, 11] have ultimately demonstrated that elevated Lp(a) levels lead to a higher risk of cardiovascular disease in the population, mainly including but not limited to my…”
Background
Metadata
- Authors
- Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., Bennett, D., Silveira, A., Malarstig, A., Green, F. R., Lathrop, M., Gigante, B., Leander, K., de Faire, U., Seedorf, U., Hamsten, A., Collins, R., Watkins, H., & Farrall, M.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Münster (DE)
- University of Surrey (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-24
- Volume
- 361
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098230963
- Cited by
- 1,671
- References
- 40
- Citations by year
- 2026: 129 · 2025: 134 · 2024: 121 · 2023: 124 · 2022: 133 · 2021: 103 · 2020: 101 · 2019: 96 · 2018: 75 · 2017: 90 · 2016: 103 · 2015: 90 · 2014: 82 · 2013: 73 · 2012: 88
- FWCI
- 73.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, LPA gene, single nucleotide polymorphisms, rs10455872, rs3798220, genetic association, 9p21
- MeSH terms
- Coronary Disease, Genetic Markers, Genotype, Humans, Myocardial Infarction, Regression Analysis, Risk Factors, Likelihood Functions, Case-Control Studies, Lipoprotein(a), Kringles, Genetic Predisposition to Disease, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.